|
|
Low-dose dual-isotope procedure planed for myocardial perfusion CZT-SPECT and assessed through a head-to-head comparison with a conventional single-isotope protocol
|
|
|
|
|
نویسنده
|
Laetitia Imbert ,Véronique Roch ,Charles Merlin ,Wassila Djaballah ,Florent Cachin ,Mathieu Perrin ,Marine Claudin ,Antoine Verger ,Henri Boutley ,Gilles Karcher ,Pierre-Yves Marie
|
منبع
|
journal of nuclear cardiology - 2018 - دوره : 25 - شماره : 6 - صفحه:2016 -2023
|
چکیده
|
purpose of the reportthis study aimed at assessing an original low-dose dual-isotope procedure in which the abnormal stress tc-99m sestamibi spect is followed by rest tl-201 spect, along with a head-to-head comparison with a single-isotope procedure. methods: and resultsone hundred two patients, referred for a low-dose stress-spect with sestamibi (123 ± 20 mbq) on a czt camera and for whom a rest sestamibi spect was warranted, had an additional tl-201 rest-spect (52 ± 5 mbq) between stress and rest sestamibi spect recordings. tl-201 images were processed for spill-over and scatter corrections, and uptake differences with stress sestamibi spect were analyzed: (1) for rest acquisitions from tl-201 (dual-isotope procedure) and from sestamibi (single-isotope procedure) and (2) in segments for which a diagnosis of ischemia, infarct, or normal perfusion was achieved. mean effective dose was 8.3 msv for dual-isotope but would decrease to 5.7 msv for an expected rate of 37% of patients for whom rest-spect is not warranted. after a further background correction of tl-201 images, the rest–stress difference in myocardial uptake was equivalent between dual- and single-procedures for identifying ischemic segments (respective areas-under-curves: 0.83 ± 0.03 and 0.81 ± 0.03). conclusion:this original dual-isotope procedure provides acceptable radiation doses and consistent results, as compared with conventional single-isotope.
|
کلیدواژه
|
Myocardial perfusion imaging ,CZT camera ,dual-isotope protocol ,Sestamibi ,thallium-201
|
آدرس
|
Université de Lorraine, Department of Nuclear Medicine, France. Nancyclotep Experimental Imaging Platform, France. Lorraine Cancerology Institute, Department of Radiotherapy, France, Université de Lorraine, Department of Nuclear Medicine, France. Nancyclotep Experimental Imaging Platform, France, Université d’Auvergne, Department of Nuclear Medicine, France, Université de Lorraine, Department of Nuclear Medicine, France. Nancyclotep Experimental Imaging Platform, France, Université d’Auvergne, Department of Nuclear Medicine, France, Université de Lorraine, Department of Nuclear Medicine, France. Nancyclotep Experimental Imaging Platform, France, Université de Lorraine, Department of Nuclear Medicine, France. Nancyclotep Experimental Imaging Platform, France, Université de Lorraine, Department of Nuclear Medicine, France. Nancyclotep Experimental Imaging Platform, France, Nancyclotep Experimental Imaging Platform, France. University of Lorraine, France, Université de Lorraine, Department of Nuclear Medicine, France. Nancyclotep Experimental Imaging Platform, France. University of Lorraine, France, Université de Lorraine, Department of Nuclear Medicine, France. Nancyclotep Experimental Imaging Platform, France
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|